RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
August 1, 2022
RegMed Investors’ (RMi) pre-open: will August be the month of my portfolio’s discontent?
July 29, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector tumbles
July 28, 2022
RegMed Investors’ (RMi) closing bell: a focus on long-term investments will ruin short and near-term portfolio performance
July 27, 2022
RegMed Investors’ (RMi) closing bell: a share pricing roller coaster session
July 26, 2022
RegMed Investors’ (RMi) closing bell: reversing the curse of the oversold at the mid-day untill struck-down
July 21, 2022
RegMed Investors’ (RMi) closing bell: when investors stare into the downside, it’s not that deep
July 21, 2022
RegMed Investors’ (RMi) pre-open: the algos are coming, share pricing on a platter
July 20, 2022
RegMed Investors’ (RMi) closing bell: upside strength sustains
July 19, 2022
RegMed Investors’ (RMi) closing bell: a relief rally, riding the high upside and rebound
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.